Rajasree Roy1, Haider Aldiwani2, Navid Darouian2, Shilpa Sharma3, Tina Torbati2, Janet Wei2, Michael D Nelson4, Chrisandra Shufelt2, Margo B Minissian2, Lian Li1, C Noel Bairey Merz2, Puja K Mehta5. 1. Emory Women's Heart Center and Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, United States of America. 2. Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, LA, CA, United States of America. 3. Internal Medicine Residency Program, Massachusetts General Hospital, Boston, MA, United States of America. 4. Department of Kinesiology, University of Texas at Arlington, United States of America. 5. Emory Women's Heart Center and Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, United States of America. Electronic address: pkmehta@emory.edu.
Abstract
BACKGROUND: Up to two-thirds of patients with obstructive coronary artery disease (CAD) have silent ischemia (SI), which predicts an adverse prognosis and can be a treatment target in obstructive CAD. Over 50% of women with ischemia and no obstructive CAD have coronary microvascular dysfunction (CMD), which is associated with adverse cardiovascular outcomes. We aimed to investigate the prevalence of SI in CMD in order to consider it as a potential treatment target. METHODS: 36 women with CMD by coronary reactivity testing and 16 age matched reference subjects underwent 24-h 12-lead ambulatory ECG monitoring (Mortara Instruments) after anti-ischemia medication withdrawal. Ambulatory ECG recordings were reviewed by two-physician consensus masked to subject status for SI measured by evidence of ≥1 minute horizontal or downsloping ST segment depression ≥1.0 mm, measured 80 ms from the J point. RESULTS: Demographics, resting heart rate, and systolic blood pressure were similar between CMD and reference subjects. Thirty-nine percent of CMD women had a total of 26 SI episodes vs. 0 episodes in the reference group (p = 0.002). Among these women 13/14 (93%) had SI, and few episodes (3/26, 12%) were symptomatic. Mean HR at the onset of SI was 96 ± 13 bpm and increased to 117 ± 16 bpm during the ischemic episodes. 87% reported symptoms that were not associated with ST depressions. CONCLUSIONS: Ambulatory ischemia is prevalent in women with CMD, with a majority being SI, while most reported symptoms were not accompanied by ambulatory ischemia. Clinical trials evaluating anti-ischemic medications should be considered in the CMD population.
BACKGROUND: Up to two-thirds of patients with obstructive coronary artery disease (CAD) have silent ischemia (SI), which predicts an adverse prognosis and can be a treatment target in obstructive CAD. Over 50% of women with ischemia and no obstructive CAD have coronary microvascular dysfunction (CMD), which is associated with adverse cardiovascular outcomes. We aimed to investigate the prevalence of SI in CMD in order to consider it as a potential treatment target. METHODS: 36 women with CMD by coronary reactivity testing and 16 age matched reference subjects underwent 24-h 12-lead ambulatory ECG monitoring (Mortara Instruments) after anti-ischemia medication withdrawal. Ambulatory ECG recordings were reviewed by two-physician consensus masked to subject status for SI measured by evidence of ≥1 minute horizontal or downsloping ST segment depression ≥1.0 mm, measured 80 ms from the J point. RESULTS: Demographics, resting heart rate, and systolic blood pressure were similar between CMD and reference subjects. Thirty-nine percent of CMD women had a total of 26 SI episodes vs. 0 episodes in the reference group (p = 0.002). Among these women 13/14 (93%) had SI, and few episodes (3/26, 12%) were symptomatic. Mean HR at the onset of SI was 96 ± 13 bpm and increased to 117 ± 16 bpm during the ischemic episodes. 87% reported symptoms that were not associated with ST depressions. CONCLUSIONS: Ambulatory ischemia is prevalent in women with CMD, with a majority being SI, while most reported symptoms were not accompanied by ambulatory ischemia. Clinical trials evaluating anti-ischemic medications should be considered in the CMD population.
Authors: Michael D Nelson; Lidia S Szczepaniak; Janet Wei; Afsaneh Haftabaradaren; Meghan Bharadwaj; Behzad Sharif; Puja Mehta; Xiao Zhang; Louise E Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz Journal: Circ Cardiovasc Imaging Date: 2014-03-14 Impact factor: 7.792
Authors: S D Buchthal; J A den Hollander; C N Merz; W J Rogers; C J Pepine; N Reichek; B L Sharaf; S Reis; S F Kelsey; G M Pohost Journal: N Engl J Med Date: 2000-03-23 Impact factor: 91.245
Authors: W J Rogers; M G Bourassa; T C Andrews; B D Bertolet; R S Blumenthal; B R Chaitman; S A Forman; N L Geller; A D Goldberg; G B Habib Journal: J Am Coll Cardiol Date: 1995-09 Impact factor: 24.094
Authors: Gregory O von Mering; Christopher B Arant; Timothy R Wessel; Susan P McGorray; C Noel Bairey Merz; Barry L Sharaf; Karen M Smith; Marian B Olson; B Delia Johnson; George Sopko; Eileen Handberg; Carl J Pepine; Richard A Kerensky Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Martha Gulati; Rhonda M Cooper-DeHoff; Candace McClure; B Delia Johnson; Leslee J Shaw; Eileen M Handberg; Issam Zineh; Sheryl F Kelsey; Morton F Arnsdorf; Henry R Black; Carl J Pepine; C Noel Bairey Merz Journal: Arch Intern Med Date: 2009-05-11
Authors: T Jake Samuel; Janet Wei; Behzad Sharif; Balaji K Tamarappoo; Varun Pattisapu; Jenna Maughan; Daisha J Cipher; Nissi Suppogu; Haider Aldiwani; Louise E J Thomson; Chrisandra Shufelt; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Michael D Nelson Journal: Int J Cardiol Date: 2021-02-02 Impact factor: 4.039
Authors: Kira Bang Bove; Marie M Michelsen; Jakob Schroder; Hannah Elena Suhrs; Daria F Bechsgaard; Naja Dam Mygind; Ahmed Aziz; Jens Kastrup; Ida Gustafsson; Eva Prescott Journal: Open Heart Date: 2021-01